Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

No quotes available
-- EUR   0.00%
07/08 3SBIO : gets nod for colorectal cancer drug clinical trial
06/03 3SBIO INC. : (01530) says ITP drug get clinical trial approval
05/20 3SBIO INC. : (01530) withdraws breast cancer drug application
SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M CNY Estimates in M CNY
Fiscal Period December 201320142015201620172018
Sales--1 6732 8343 5174 162
Operating income (EBITDA)--6921 1181 3801 609
Operating profit (EBIT)--6149291 1711 350
Pre-Tax Profit (EBT)------
Net income--5267641 0071 210
P/E ratio--39,625,018,915,7
EPS ( CNY )--0,230,300,390,48
Dividend per Share ( CNY )----0,010,01
Yield----0,11%0,13%
Reference price ( CNY )9.117.472297.472297.47229
Announcement Date--03/31/2016
11:12am
---
Finances - Leverage
Actuals in M CNY Estimates in M CNY
Fiscal Period December 201320142015201620172018
Debt---701--
Finance--894-1571 116
Operating income (EBITDA)--6921 1181 3801 609
Leverage
(Debt/EBITDA)
---0,63x--
Capital Expenditure--61,0122133131
Book Value Per Share (BVPS)--2,24  CNY2,41  CNY2,78  CNY3,32  CNY
Cash Flow per Share--0,20  CNY0,32  CNY0,40  CNY0,50  CNY
Announcement Date01/01/1970
01:00am
01/01/1970
01:00am
03/31/2016
11:12am
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 18 907 M CNY -
Entreprise Value (EV) 19 608 M CNY 18 750 M CNY
Valuation 2016e 2017e
P/E ratio (Price / EPS) 25,0x 18,9x
Capitalization / Revenue 6,67x 5,38x
EV / Revenue 6,92x 5,33x
EV / EBITDA 17,5x 13,6x
Yield (DPS / Price) - 0,11%
Price to book (Price / BVPS) 3,11x 2,68x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 32,8% 33,3%
operating Leverage (Delta EBIT / Delta Sales) 0,74x 1,08x
Net Margin (Net Profit / Revenue) 27,0% 28,6%
ROA (Net Profit / Asset) 9,27% 10,2%
ROE (Net Profit / Equities) 12,5% 14,6%
Rate of Dividend - 2,03%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   4,32% 3,79%
Cash Flow / Sales 28,8% 28,9%
Capital Intensity (Assets / Sales) 2,91x 2,82x
Financial Leverage (Net Debt / EBITDA) 0,63x -0,11x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend